氢化可的松、维生素C和硫胺素治疗严重脓毒症和脓毒性休克:一项前后对照的回顾性研究。
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study.
作者信息
Marik Paul E, Khangoora Vikramjit, Rivera Racquel, Hooper Michael H, Catravas John
机构信息
Division of Pulmonary and Critical Care Medicine, Eastern Virginia Medical School, Norfolk, VA.
Division of Pulmonary and Critical Care Medicine, Eastern Virginia Medical School, Norfolk, VA.
出版信息
Chest. 2017 Jun;151(6):1229-1238. doi: 10.1016/j.chest.2016.11.036. Epub 2016 Dec 6.
BACKGROUND
The global burden of sepsis is estimated as 15 to 19 million cases annually, with a mortality rate approaching 60% in low-income countries.
METHODS
In this retrospective before-after clinical study, we compared the outcome and clinical course of consecutive septic patients treated with intravenous vitamin C, hydrocortisone, and thiamine during a 7-month period (treatment group) with a control group treated in our ICU during the preceding 7 months. The primary outcome was hospital survival. A propensity score was generated to adjust the primary outcome.
RESULTS
There were 47 patients in both treatment and control groups, with no significant differences in baseline characteristics between the two groups. The hospital mortality was 8.5% (4 of 47) in the treatment group compared with 40.4% (19 of 47) in the control group (P < .001). The propensity adjusted odds of mortality in the patients treated with the vitamin C protocol was 0.13 (95% CI, 0.04-0.48; P = .002). The Sepsis-Related Organ Failure Assessment score decreased in all patients in the treatment group, with none developing progressive organ failure. All patients in the treatment group were weaned off vasopressors, a mean of 18.3 ± 9.8 h after starting treatment with the vitamin C protocol. The mean duration of vasopressor use was 54.9 ± 28.4 h in the control group (P < .001).
CONCLUSIONS
Our results suggest that the early use of intravenous vitamin C, together with corticosteroids and thiamine, are effective in preventing progressive organ dysfunction, including acute kidney injury, and in reducing the mortality of patients with severe sepsis and septic shock. Additional studies are required to confirm these preliminary findings.
背景
据估计,全球每年脓毒症病例数为1500万至1900万,在低收入国家死亡率接近60%。
方法
在这项回顾性前后对照临床研究中,我们比较了在7个月期间接受静脉注射维生素C、氢化可的松和硫胺治疗的连续性脓毒症患者(治疗组)与前7个月在我们重症监护病房接受治疗的对照组的结局和临床病程。主要结局是住院生存率。生成倾向评分以调整主要结局。
结果
治疗组和对照组均有47例患者,两组基线特征无显著差异。治疗组的医院死亡率为8.5%(47例中的4例),而对照组为40.4%(47例中的19例)(P <.001)。接受维生素C方案治疗的患者经倾向调整后的死亡 odds 为0.13(95%CI,0.04 - 0.48;P =.002)。治疗组所有患者的脓毒症相关器官功能衰竭评估评分均下降,且无患者发生进行性器官功能衰竭。治疗组所有患者均停用血管升压药,在开始使用维生素C方案治疗后平均18.3±9.8小时。对照组血管升压药的平均使用时间为54.